Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization
出版年份 2016 全文链接
标题
Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization
作者
关键词
-
出版物
HEPATOLOGY
Volume 64, Issue 4, Pages 1105-1120
出版商
Wiley
发表日期
2016-05-14
DOI
10.1002/hep.28637
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
- (2014) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Necessary and Sufficient Role for a Mitosis Skip in Senescence Induction
- (2014) Yoshikazu Johmura et al. MOLECULAR CELL
- Polo-like kinases: structural variations lead to multiple functions
- (2014) Sihem Zitouni et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism
- (2013) Ariel Pribluda et al. CANCER CELL
- Requirements for Aurora-A in Tissue Regeneration and Tumor Development in Adult Mammals
- (2013) I. Perez de Castro et al. CANCER RESEARCH
- Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer--From Molecular Mechanism to Therapeutic Application
- (2013) S. Fulda CLINICAL CANCER RESEARCH
- Hepatic loss of survivin impairs postnatal liver development and promotes expansion of hepatic progenitor cells in mice
- (2013) Dan Li et al. HEPATOLOGY
- T-helper-1-cell cytokines drive cancer into senescence
- (2013) Heidi Braumüller et al. NATURE
- NAFLD, NASH and liver cancer
- (2013) Gregory A. Michelotti et al. Nature Reviews Gastroenterology & Hepatology
- Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation
- (2013) H. Walczak Cold Spring Harbor Perspectives in Biology
- A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
- (2012) K Mross et al. BRITISH JOURNAL OF CANCER
- Targeting survivin in cancer
- (2012) Dario C. Altieri CANCER LETTERS
- A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
- (2012) Peter M. Ellis et al. Clinical Lung Cancer
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin
- (2012) Lihua Min et al. NATURE CELL BIOLOGY
- Cancer drug's survivin suppression called into question
- (2012) David Holmes NATURE MEDICINE
- The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
- (2012) Mar Carmena et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Senescence: a new weapon for cancer therapy
- (2012) Juan Carlos Acosta et al. TRENDS IN CELL BIOLOGY
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
- (2011) Tae-Won Kang et al. NATURE
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program
- (2011) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
- Survivin and IAP proteins in cell-death mechanisms
- (2010) Dario C. Altieri BIOCHEMICAL JOURNAL
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- (2010) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial
- (2010) Martin Sebastian et al. Journal of Thoracic Oncology
- Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
- (2010) B. J. Tunquist et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
- (2009) Karl D. Lewis et al. INVESTIGATIONAL NEW DRUGS
- Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer
- (2009) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5
- (2008) J. Shi et al. CANCER RESEARCH
- TNF-α Induces Two Distinct Caspase-8 Activation Pathways
- (2008) Lai Wang et al. CELL
- Senescence of Activated Stellate Cells Limits Liver Fibrosis
- (2008) Valery Krizhanovsky et al. CELL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started